Literature DB >> 3691650

Cardiovascular effects of L-tyrosine in normotensive and hypertensive rats.

S Ekholm1, H Karppanen.   

Abstract

There are conflicting reports on the blood pressure effects of tyrosine. The aim of this study was to establish complete dose-response relationships and to compare the effects of various modes of administration of L-tyrosine in anaesthetised normotensive and spontaneously hypertensive rats. The intravenous injection of L-tyrosine, 0.2-0.4 mmol/kg, produced tachycardic and hypertensive effects in both species. The higher doses (0.8-1.6 mmol/kg) produced marked bradycardiac and hypotensive responses. Intracerebroventricular administration of L-tyrosine, 0.005-0.1 mmol/kg, had no statistically significant effects. Chronic dietary administration of L-tyrosine at the approximate daily doses of 0.7-55 mmol/kg was also without any significant effects. These results suggest that the controversies in the earlier studies could be due mainly to differences in doses and modes of administration. Our results also suggest that the cardiovascular effects of tyrosine are peripheral rather than central in origin although a central site of action cannot be excluded.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3691650     DOI: 10.1016/0014-2999(87)90731-x

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  2 in total

1.  Enhanced functional connectivity and volume between cognitive and reward centers of naïve rodent brain produced by pro-dopaminergic agent KB220Z.

Authors:  Marcelo Febo; Kenneth Blum; Rajendra D Badgaiyan; Pablo D Perez; Luis M Colon-Perez; Panayotis K Thanos; Craig F Ferris; Praveen Kulkarni; John Giordano; David Baron; Mark S Gold
Journal:  PLoS One       Date:  2017-04-26       Impact factor: 3.240

Review 2.  Administration of supplemental L-tyrosine with phenelzine: a clinical literature review.

Authors:  Marty Hinz; Alvin Stein; Ted Cole; Patricia Ryan
Journal:  Clin Pharmacol       Date:  2014-07-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.